FRAZER, Pa., Jan. 4 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that Frank Baldino, Jr., Ph.D., Chairman and CEO will present at the JP Morgan Healthcare Conference being held at the Westin St. Francis Hotel in San Francisco, CA. Dr. Baldino will deliver a one hour presentation on Tuesday, January 8, 2008 beginning at 2:00 p.m. Pacific Time (11 a.m. Eastern Time).
Live Web Cast and Archived Replay
Members of the financial and investment community, the media and other interested parties can access a live web cast of the presentation through the investor relations section of the company's website http://www.cephalon.com. Following the live presentation, a replay of the presentation will be available for two weeks on the company's website.
About Cephalon, Inc.
Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. Cephalon's European headquarters are located in Maisons-Alfort, France.
The company's proprietary products in the United States include: PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA(R) (fentanyl buccal tablet) [C-II], TRISENOX, AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.
|SOURCE Cephalon, Inc.|
Copyright©2008 PR Newswire.
All rights reserved